key: cord-0795953-7atns5na authors: Zhu, Ling; Deng, Yong-Qiang; Zhang, Rong-Rong; Cui, Zhen; Sun, Chun-Yun; Fan, Chang-Fa; Xing, Xiaorui; Huang, Weijin; Chen, Qi; Zhang, Na-Na; Ye, Qing; Cao, Tian-Shu; Wang, Nan; Wang, Lei; Cao, Lei; Wang, Huiyu; Kong, Desheng; Ma, Juan; Luo, Chunxia; Zhang, Yanjing; Nie, Jianhui; Sun, Yao; Lv, Zhe; Shaw, Neil; Li, Qianqian; Li, Xiao-Feng; Hu, Junjie; Xie, Liangzhi; Rao, Zihe; Wang, Youchun; Wang, Xiangxi; Qin, Cheng-Feng title: Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2 date: 2020-12-18 journal: Natl Sci Rev DOI: 10.1093/nsr/nwaa297 sha: 622e2268de1b6aab9bfa57660f785e4f06c5048c doc_id: 795953 cord_uid: 7atns5na Receptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10-fold of effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the RBD, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19. Like, SARS-CoV, SARS-CoV-2 utilizes its protuberant S glycoprotein to engage with its cellular receptor, human angiotensin converting enzyme 2 (ACE2), for forging membrane fusion in order to enter host cell (4, 5) . Each monomeric S protein can be cleaved by host proteases, such as TMPRSS2 (5, 6) into two functional domains, the distal globular S1 domain and the membrane-proximal S2 domain, which mediate receptor binding and membrane fusion, respectively (7) . The S1 subunit consists of an N-terminal domain (NTD) and a C-terminal domain, which often functions as the receptor binding domain (RBD). Conformational transitions are triggered upon release of the S1 subunit after receptor binding and subsequent priming of the protein by host cell proteases. These two key events advance the life-cycle of the virus from the prefusion to the postfusion stage, leading to the fusion of the viral membrane with that of the host cell (7, 8) . Phage display identifies a potent SARS-CoV-2 specific NAb We previously identified a set of NAbs from an antibody library which was generated from RNAs extracted from peripheral lymphocytes of mice immunized with recombinant SARS-CoV RBD protein (29). In this study, we constructed another antibody library by immunizing mice with recombinant SARS-CoV-2 RBD, which yielded a chimeric anti-SARS-CoV-2 mAb, named mhB27. mhB27 was able to strongly bind to SARS-CoV-2 RBD and exhibited potent neutralizing activities against SARS-CoV-2 when tested in a vesicular stomatitis virus (VSV) pseudotyping Histopathological examination revealed moderate interstitial pneumonia, characterized by inflammatory cell infiltration, alveolar septal thickening and distinctive vascular system injury developed in hACE2 humanized mice belonging to the PBS control group at day 5 ( Figure 2G ). In contrast, the lungs in mice from the HB27 treated group only showed minimal or very mild inflammatory cell infiltration, and no obvious lesions of alveolar epithelial cells or focal hemorrhage ( Figure 2G ). Collectively, these results clearly demonstrated the utility of HB27 for prophylactic or therapeutic purposes against SARS-CoV-2. Evaluation of the safety of administration of HB27 in non-human primates Table S1 . These results suggest that HB27 probably has pharmacokinetic properties consistent with a typical human IgG1. Hematological and biochemical analysis, including biochemical blood tests and lymphocyte subset percent (CD4 + and CD8 + ) showed no notable changes in the HB27 administrated group when compared to the placebo group ( Figure 3B-3D ). Taken together, the results of our animal studies indicate that HB27 is generally safe in non-human primates. HB27 prevents the attachment of SARS-CoV-2 to host cells by blocking its binding to ACE2 To evaluate the ability of HB27 to inhibit binding of RBD to ACE2, we performed competitive binding assays at both protein and cellular levels. Results of the enzyme-linked immunosorbent assay (ELISA) revealed that HB27 could prevent the binding of soluble ACE2 (monomer in solution) to SARS-CoV-2 RBD with an EC 50 value of 0.5 nM ( Figure S2A ). To verify the ability of HB27 to block the binding of ACE2 to trimeric S, we expressed and purified stabilized SARS-CoV-2 S ectodomain trimer. Surface plasmon resonance (SPR) assays indicated that HB27 interacts with SARS-CoV-2 S trimer with a slightly stronger binding affinity (~0.04 nM) ( Figure S2B ), which was about 1000-fold higher than that of soluble ACE2 with SARS-CoV-2 S ( Figure S2C ) (6) . For the competitive SPR, two sets of assays: exposing the trimeric S to HB27 first and then to soluble ACE2, or the other way around, were conducted. As expected, binding of HB27 completely blocked the interaction between soluble ACE2 and SARS-CoV-2 trimeric S. Moreover, soluble ACE2 that had already bound to trimeric S could be replaced by HB27 because of the to host cell surface at sub-nM and could displace the virions that had already bound to the cell surface at ~2.5 nM ( Figure 4C ). A common way to determine whether the antibody inhibits virus-receptor binding or a post-attachment step of the infection is to compare neutralization curves deduced from mixing antibody with the virus before or after binding to cells at 4 °C. The assumption is antibodies that inhibit receptor binding will not have a neutralizing effect on virus that has already bound to its receptor. However, this assumption may not be true, because high-affinity antibodies could possibly displace the virus that is already complexed to a low-affinity receptor, as observed for HB27 ( Fig. 4B-4C ). Thus, deriving the mechanism of neutralization by just conducting neutralization assays may not yield the complete picture, although pre-and post-attachment neutralization assays suggested that HB27 inhibits a post-attachment step of the infection ( Figure 5A ). In coronaviruses, receptor binding and proteolytic processing act in synergy to trigger a series of conformational changes in S, bringing viral and cellular membranes in proximity for fusion, leading to establishment of infection (8) . TMPRSS2-mediated cleavage is capable of activating the fusion potential of coronavirus S proteins, inducing receptor-dependent syncytium formation, which was recently observed in natural SARS-CoV-2 infections as well (33, 34). To explore whether HB27 could interfere with syncytium formation, we established the S-mediated cell-cell fusion system using 293T cells that express SARS-CoV-2 S with a GFP tag as the effector cells and Vero-E6 cells as the target cells ( Figure 5B ). After Figure 5D ). The blockage of membrane fusion by HB27 is likely another important mechanism of neutralization. However, given the relatively higher concentration of HB27 needed to block viral membrane fusion, blocking viral attachment to its host cell receptor is likely to be the main mechanism of neutralization. Structural basis for the SARS-CoV-2 specific binding of HB27 To delineate the structural basis for HB27-mediated specific neutralization, we determined the cryo-EM structure of a prefusion stabilized SARS-CoV-2 S ectodomain trimer in complex with the HB27 Fab fragment using single particle reconstruction. Similar to previously published studies on apo SARS-CoV-2 S trimer, two distinct conformational states referred to as the "close" and "open" RBDs were observed in the structure of the complex ( Figure 6A ). Cryo-EM characterization of the complex showed full occupancy with one Fab bound to each RBD of the homotrimeric S. We asymmetrically reconstructed the complex structure at an overall resolution of 3.5 Å, which represents two "open" and one "close" RBDs ( Figure 6A , Table S2 ). The initial maps for the binding interface between RBD and HB27 were relatively weak due to conformational heterogeneity, which is in line with the structural observations of stochastic RBD rotations at different angles while switching from the "closed" to "open" states ( Figure 6B-6C) . In order to improve the local resolution, we employed a "block-based" reconstruction approach, which resulted in a 3.9 Å resolution, enabling reliable analysis of the interaction interface ( Figure S3-S4 ). HB27 binds to the apical head of RBD, partially overlapping with the edge of the RBM core. This binding was independent of glycan recognition ( Figure 6D-6E) . The head of RBD inserts into the cavity constructed by five complementarity determining regions (CDRs, CDRL1, CDRL3 and CDRH1-3), involving extensive hydrophobic interactions ( Figure 6F ). The heavy and light chains bury ~500 Å 2 and ~210 Å 2 of the surface area of the epitope, respectively. Tight binding is further facilitated by 5 hydrogen bonds ( Figure 6G and Table S3 ). HB27 epitope includes 12 residues, of which only 7 residues are conserved between SARS-CoV-2 and SARS-CoV, explaining its specificity for SARS-CoV-2 for binding and neutralization ( Figure S5A ). Although a number of point mutations in the RBD have been reported in currently circulating strains, none of these mutations lie within the HB27 epitope ( Figure S5A ). To test the spectrum of neutralizing activities of HB27 against currently circulating strains of SARS-CoV-2, RBD mutants bearing various amino acid substitutions reported were expressed and evaluated for their binding affinities to HB27. In line with structural analysis, all the RBD mutants exhibited comparable binding abilities ( Figure S5B ). More recently, SARS-CoV-2 isolates encoding a D614G mutation in the C-terminal region of the S1 predominate (35). To investigate the neutralizing activities against this more contagious isolate, SARS-CoV-2 PSV harboring the D614G mutation was constructed. Compared to the wild type, HB27 showed similar binding affinities and neutralizing activities against the D614G mutant Results of our functional studies revealed that HB27 could completely block the interactions of SARS-CoV-2 with ACE2 ( Figure 4) . To decipher the structural basis for this ability of HB27, the complex structures of SARS-CoV-2 trimer/HB27-Fab and SARS-CoV-2 RBD/ACE2 were superimposed. The superimposition of the structures revealed that HB27 could sterically hinder ACE2 binding ( Figure 7A ). Out of the 12 residues in the HB27 epitope, 7 residues are involved in tight contacts with ACE2 ( Figure 6E and Figure S7 ). In addition, the three HB27 Fabs act in synergy to abolish ACE2 binding, in which binding of any one ACE2 molecule is sterically hindered by two adjacent HB27 ( Figure Our results indicate that HB27 probably inhibits SARS-CoV-2 infection at multiple steps during the viral entry process. First, viral infection can be stalled by hindering the attachment of SARS-CoV-2 to host cells by preventing interactions between the RBD and ACE2, which is the major neutralization mechanism for most RBD-targeting NAbs. Upon virus attachment and entry into host cells, proteolytic activation at the S1/S2 boundary leads to S1 dissociation and a dramatic structural change in S2, which triggers viral membrane fusion (6) . To date, antibodies that are and translucent molecular surfaces with three monomers colored in cyan, yellow and violet, respectively. The three copies of HB27 Fabs are rendered as molecular surfaces colored the same as in Figure 6 . The superposed ACE2 is presented as green ribbon diagrams as well as translucent molecular surface. Insets are close-up views of the clashes between ACE2 and HB27 upon binding to SARS-CoV-2 RBD. (B) Orthogonal views of the structure of HB27 Fab-A, Fab-B and Fab-C complexed with SARS-CoV-2 RBD. The S1 subunits of SARS-CoV-2 S trimer are rendered as cyan, yellow and violet surfaces and the S2 subunits are rendered as gray surfaces. A pneumonia outbreak associated with a new coronavirus of probable bat origin Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Development of an inactivated vaccine candidate for SARS-CoV-2 Coronavirus spike proteins in viral entry and pathogenesis SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cell entry mechanisms of SARS-CoV-2 Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual review of virology Pre-fusion structure of a human coronavirus spike protein Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody The spike protein of SARS-CoV--a target for vaccine and therapeutic development Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus